Suvi T. M. Orr

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Simon Planken, Douglas C. Behenna, Sajiv K. Nair et al. · Journal of Medicinal Chemistry · 2017 · 89 citations · Full text

Molecular Biology, Wild-type Egfr, Chemical Biology +21

Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)

Kentaro Futatsugi, Daniel W. Kung, Suvi T. M. Orr et al. · Journal of Medicinal Chemistry · 2015 · 80 citations

Combinatorial Chemistry, Lipid Analysis, Medicinal Chemistry +14

Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.

L H Patterson, S. R. McKeown, Tracy Robson et al. · PubMed · 1999 · 77 citations

Molecular Pharmacology, Cyp3a Mrna, Chemoprevention Strategy +12

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate

Samit K. Bhattacharya, Kim Andrews, Ramsay E. Beveridge et al. · ACS Medicinal Chemistry Letters · 2014 · 67 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +10

Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2<i>H</i>)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases

Roger B. Ruggeri, Leonard Buckbinder, Scott W. Bagley et al. · Journal of Medicinal Chemistry · 2015 · 57 citations · Full text

Lipid Peroxidation, Cardiovascular Pharmacology, Pharmacotherapy +16